**Structured feedback on**

***GLASS early implementation protocol for inclusion of* Candida *spp***

***Context***

The emergence of multi-drug resistant *Candida* species causing severe systemic infection frequently resulting in outbreaks highlights the need for action informed by global data. The ***GLASS early implementation protocol for the inclusion of* Candida *spp***.[[1]](#footnote-1) aims to promote national surveillance and global monitoring of this public health threat.

This ***GLASS early implementation protocol for the inclusion of* Candida *spp*** was developed to support countries to strengthen or build their national fungal AMR surveillance, and enable incorporation of AMR surveillance for invasive *Candida* into GLASS. The protocol describes the objectives and methodology, and provides details of the proposed approach and defined targets for the surveillance of resistance in *Candida* spp causing bloodstream infections. This protocol will guide countries to design their surveillance system or determine how to leverage their existing system for GLASS, and to build the capacity needed for AMR surveillance of *Candida* spp., as well as coordinate the related surveillance activities.

***Questionnaire***

This questionnaire is intended to obtain feedback from countries on the document ***GLASS early implementation protocol for the inclusion of* Candida *spp*** and also on the feasibility for its application in your country.

Please discuss this questionnaire with colleagues in charge of AMR surveillance in your country to ensure the responses reflect the views and experience of national AMR surveillance in your country. Please provide one consolidated response for your country.

The responses should be submitted through the online version of this questionnaire found on the GLASS 2020 platform.

Thank you for your support to the development of GLASS!

**1: Is the document *GLASS early implementation protocol for the inclusion of* Candida *spp* presented in a clear manner?**

|  |  |
| --- | --- |
| Yes |  |
| No |  |
| Don't know |  |

If your response is ‘No’: What is missing in the presentation of the *GLASS early implementation protocol for the inclusion of* Candida *spp*?

|  |
| --- |
|  |
|  |
|  |

**2: Does the *GLASS early implementation protocol for the inclusion of* Candida *spp* provide a clear guidance to support the implementation of the AMR surveillance in *Candida* spp in countries?**

|  |  |
| --- | --- |
| Yes |  |
| No |  |
| Don't know |  |

If your response is ‘No’: What is missing in the *GLASS early implementation protocol for the inclusion of* Candida *spp* in terms of providing a clear guidance for countries?

|  |
| --- |
|  |
|  |
|  |

**3: Does the *GLASS early implementation protocol for the inclusion of* Candida *spp* present clearly a) requirements and b) definitions for implementing AMR surveillance in *Candida* spp?**

|  |  |
| --- | --- |
| Yes |  |
| No |  |
| Don't know |  |

If your response is ‘No’: What is missing in the *GLASS early implementation protocol for the inclusion of* Candida *spp* in terms of:

a) Requirements for implementing AMR surveillance in *Candida* spp?

|  |
| --- |
|  |
|  |
|  |

b) Definitions for implementing AMR surveillance in *Candida* spp?

|  |
| --- |
|  |
|  |
|  |

**4: Do you find the *GLASS early implementation protocol for the inclusion of* Candida *spp* useful for assisting with enhancing AMR surveillance system in your country?**

|  |  |
| --- | --- |
| Yes |  |
| No |  |
| Don't know |  |

If your response is ‘No’: What is missing in the *GLASS early implementation protocol for the inclusion of* Candida *spp* for you to find it useful for assisting with enhancing AMR surveillance system in your country?

|  |
| --- |
|  |
|  |
|  |

**5: Are bloodstream infections due to *Candida* spp systematically monitored in your country?**

|  |  |
| --- | --- |
| Yes |  |
| No |  |
| Don't know |  |

If your response is ‘Yes’: Please indicate the approximate frequency of bloodstream infections due to *Candida* spp in your country.

|  |
| --- |
|  |
|  |
|  |

**6: Do you consider that the clinical laboratories participating in the national AMR surveillance system have the capacity and infrastructure required for identification and performing antifungal susceptibility testing (AFST) of *Candida* spp?**

|  |  |
| --- | --- |
| Yes |  |
| No |  |
| Don't know |  |

If your response is ‘No’: What do you consider is necessary to increase the capacity and infrastructure in your country in terms of identification and performing AFST?

|  |
| --- |
|  |
|  |
|  |

**7: Would you consider the implementation of *GLASS early implementation protocol for the inclusion of* Candida *spp* as part of your AMR national surveillance system?**

|  |  |
| --- | --- |
| Yes |  |
| No |  |
| Don't know |  |

What would be required to implement the *GLASS early implementation protocol for the inclusion of* Candida *spp* in the national AMR surveillance system?

|  |
| --- |
|  |
|  |
|  |

**8:** **Please share any additional comments you have on the *GLASS early implementation protocol for the inclusion of* Candida *spp*.**

|  |
| --- |
|  |
|  |
|  |

1. WHO, 2019. GLASS early implementation protocol for inclusion of Candida spp <https://apps.who.int/iris/handle/10665/326926>. [↑](#footnote-ref-1)